ABN Amro Investment Solutions Makes New $916,000 Investment in STERIS plc $STE

ABN Amro Investment Solutions bought a new stake in shares of STERIS plc (NYSE:STE) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,143 shares of the medical equipment provider’s stock, valued at approximately $916,000.

A number of other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. increased its position in STERIS by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock worth $3,114,882,000 after purchasing an additional 73,014 shares during the last quarter. State Street Corp grew its position in STERIS by 6.0% in the fourth quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock worth $1,169,957,000 after acquiring an additional 260,001 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of STERIS by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 2,523,620 shares of the medical equipment provider’s stock worth $637,259,000 after purchasing an additional 14,151 shares during the last quarter. Orbis Allan Gray Ltd increased its stake in shares of STERIS by 5.6% during the 4th quarter. Orbis Allan Gray Ltd now owns 2,249,511 shares of the medical equipment provider’s stock worth $570,296,000 after purchasing an additional 120,200 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of STERIS by 37.2% during the 4th quarter. AQR Capital Management LLC now owns 1,623,234 shares of the medical equipment provider’s stock valued at $411,522,000 after purchasing an additional 440,164 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Activity

In other news, VP John Adam Zangerle sold 1,419 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $209.28, for a total value of $296,968.32. Following the sale, the vice president directly owned 35,259 shares in the company, valued at approximately $7,379,003.52. This represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total value of $310,284.31. Following the completion of the transaction, the director directly owned 38,964 shares of the company’s stock, valued at approximately $8,163,347.64. The trade was a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 7,328 shares of company stock worth $1,554,051. Company insiders own 1.12% of the company’s stock.

STERIS Trading Up 1.7%

Shares of STE opened at $214.16 on Friday. The stock’s 50-day moving average price is $211.69 and its 200 day moving average price is $227.60. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $20.87 billion, a price-to-earnings ratio of 27.01 and a beta of 0.92. STERIS plc has a 12-month low of $195.14 and a 12-month high of $269.44.

STERIS (NYSE:STE) last announced its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.STERIS’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, research analysts predict that STERIS plc will post 11.18 earnings per share for the current year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 26th. Shareholders of record on Monday, June 8th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend was Monday, June 8th. STERIS’s payout ratio is presently 31.78%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. KeyCorp reduced their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Weiss Ratings lowered shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Piper Sandler reiterated an “overweight” rating and issued a $270.00 target price on shares of STERIS in a report on Thursday, May 21st. Finally, Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $278.00.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.